chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a medical assistant via field representative referring to a male patient of unknown age. Patient's concurrent condition included anxiety. His relevant medical history and drug reactions/ allergies were unspecified. On an unspecified date in July 2015 (reported as within the last two weeks), the patient was vaccinated with intramuscular dose of GARDASIL (strength, dose, frequency, lot # unspecified). It was confirmed that the vaccine was not GARDASIL 9. Concomitant therapies included Tdap and MENACTRA. Reporting medical assistant stated that the patient fainted in the office after receiving vaccination with GARDASIL. Patient sought medical attention on an unspecified date. No treatment was given for the adverse event. Reporting medical assistant stated that the patient decided not to complete the vaccination series with GARDASIL (inappropriate schedule of drug administration). Outcome of the event, syncope was reported as recovered. Reporting medical assistant did not assessed the causality of the event with respect to vaccination with GARDASIL. Additional information is not expected as the reporter did not wish further contact.
The patient came to the consultation counter with a raised rash in the immunized arm. I put gloves on to examine the placement of the vaccince since he still had his bandaid on and it was administered within his L Deltoid muscle. His arm was also hot to touch and the rash was raised. I advised the patient to visit an urgent care center or go to his doctor so that he could receive treatment. The patient informed me that he had an appointment already scheduled for the next day and asked what could he do in the mean time. I made sure to ask him if he was experiencing any SOB/chest tightness/difficulty breathing and  he confirmed that he was not so I recommended that he take benadryl to help with the reaction that he was experiencing until he made it to his appointment.
4 days following TDAP booster, developed polyarthritis - hands, wrists, elbows. Diminished, but partially prevalent symptoms after 3 months.
Patient reports that "a bump appeared within a week of receiving the influenza vaccine last year and has never gone away since." Patient also reports that the bump has never given her any issues. Patient reported event today 10/21/14 before receiving 2014/2015 influenza vaccine in right deltoid.
From initial information received on 17Sep04 from a RN regarding an adverse event occurring, it was reported that a one year old male pt received an Acthib vaccination, lot number UE424AA, administered IM in the left thigh, and an IPOL vaccination, lot number X1189, administered SC in the left arm on 15Sep04. Later that same evening, the pt's mother called the physician's office and reported that the pt had a rectal temp of 104.0 degrees F, a pacing heart rate and fussiness. On 16Sep04, the pt rectal temp was reported as 104.0 degrees F. On 17Sep04, the pt's rectal temp was 100 F. The pt was treated with Motrin and was eating well. His recovery status was not reported. The reporter of this case is the same reporter as cases 200403063. Follow up - From additional information received on 11/Mar/2005 from a registered nurse, it was reported that the patient had one previous dose of ACTHIB and two previous doses of IPOL. On 16/Sep/2004, the patient's temperature was 104 degrees Fahrenheit and heart rate and respiratory rate were increased. On 17/Sep/2004, the patient's temperature was 100 degrees Fahrenheit. He was seen again by the physician on 18/Sep/2004. At that time, the patient had a temperature of 96.0 degrees Fahrenheit and CBC and Blood Culture tests were performed. At the time of this report, the patient has recovered from thiese events. No further information is anticipated, this case is considered closed.
Deep bone pain in left elbow radiating down arm, Weakness in left arm. Deep pain in neck, especially bones in the back of skull. The pain is constant. No amount of over the counter pain relievers have helped. I have needed to take these daily because the pain is constant ever since this vaccine was given to me.
Initial information was received on 23 December 2008 from a health care professional. A one year old male patient with a runny nose at the time of vaccination received an intramuscular left thigh injection of FLUZONE No Preservative 2008-2009 (lot number UT2782EA) on 17 November 2008. A few days post vaccination the child had twitching of the body and head jerking. The symptoms ended but began to occur again. The symptoms were more pronounced and lasted for ten minute intervals. The patient required a doctor's visit. The patient was not recovered at the time of the report. No further information was provided. List of Documents held by Sender: None.
None stated. 11/25/09:  Hospital records received for dates of service 9/24/09 to 9/25/09.  Dx:  Anaphylactic reaction to immunization and asthma.  Developed wheezing, coughing and urticarial rash with swelling of eyelids and lips one half hour after immunizations.  Red area around injection site. Admitted to CCU.   Steroid therapy, albuterol and benadryl  and IV therapy initiated.  Discharge in improved condition.
Unspecific adverse event.; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION COMPLICATION (Unspecific adverse event.) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Unspecific adverse event.). At the time of the report, VACCINATION COMPLICATION (Unspecific adverse event.) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
I got the vaccine at 11:30 a.m.  About 8:30 p.m., I started to feel achy.  At 9:30 p.m.  I felt really achy.  At 10:00 p.m.  I had slight chills, and my hands felt colder than I had ever felt them before.  At 10:30 p.m., I felt slightly nauseous.  I went to bed then.  When I woke up the next morning about 7:30 a.m., my body felt fine, but my brain was a bit foggy.  This continued until about 12:00 p.m.  After that, I was fine.
frozen shoulder; This spontaneous case was reported by a patient and describes the occurrence of PERIARTHRITIS (frozen shoulder) in a female patient of an unknown age who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced PERIARTHRITIS (frozen shoulder). The patient was treated with CORTISONE for Frozen shoulder, at an unspecified dose and frequency. At the time of the report, PERIARTHRITIS (frozen shoulder) had resolved.        The action taken with mRNA-1273 (Spikevax) (Unknown) was unknown.       No concomitant information were reported by the reporter.  It was reported after first dose patient had frozen shoulder and did not go until patient had a cortisone shot.  Company Comment: This is a spontaneous case concerning a female patient of unknown age, with no reported medical history, who experienced the unexpected non-serious AESI Periarthritis (frozen shoulder) which occurred unknown number of days after receiving the 1st dose of mRNA-1273 Vaccine. As reported, a weekend after her first dose, patient had a frozen shoulder that did not go away until she had a cortisone shot. There is no available information regarding diagnostic tests/procedures. The patient's gender remains a predisposition risk factor for the event. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.   This case was linked to US-MODERNATX, INC.-MOD-2022-628875 (Linked Report).; Sender's Comments: This is a spontaneous case concerning a female patient of unknown age, with no reported medical history, who experienced the unexpected non-serious AESI Periarthritis (frozen shoulder) which occurred unknown number of days after receiving the 1st dose of mRNA-1273 Vaccine. As reported, a weekend after her first dose, patient had a frozen shoulder that did not go away until she had a cortisone shot. There is no available information regarding diagnostic tests/procedures. The patient's gender remains a predisposition risk factor for the event. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. US-MODERNATX, INC.-MOD-2022-628875:Reporter's case
Information has been received from a female patient (an epidemiologist from the CDC) who reported that she received a dose of ZOSTAVAX (Merck) intramuscularly rather than subcutaneously on the morning of 06-OCT-2011. No adverse event reported. The patient sought no medical attention. Follow up information has been received from the HCP (Ph.D.) who reported on herself received the second dose of ZOSTAVAX (Merck) on an unspecified date (lot # and route not reported). The patient developed respiratory and gastrointestinal (GI) viral infection 1 weeks after receiving ZOSTAVAX (Merck) IM and both events were resolved, and then developed episcleritis 1 weeks after that (so 2 weeks after receiving ZOSTAVAX (Merck)). The patient was trying to resolve episcleritis as of now and was being seen by an ophthalmologist. Follow-up information was received via Vaccine Adverse Event Reporting System (VAERS) form from 61 year old female epidemiologist reporting on herself. Patient was vaccinated at a private doctor's office/hospital. The patient received a flu shot (manufacturer unknown) on her left arm on 04-OCT-2011. On 06-OCT-2011 the patient received first dose of ZOSTAVAX in her left arm muscle in the morning. Lot number of ZOSTAVAX not reported. Patient was well at the time of flu and shingles shots. Vaccine was administered in a private doctor's office/hospital. Patient also stated that an adverse event should be filed as she had a severe episcleritis in her right eye for half a year after her shingles shot. The event had resolved on approximately May 2012 (late spring of 2012). Additional information is not expected.
8AUG91 vax given @ 830AM; Antipyretic given; went to sleep @ 3PM up @ 5PM w/temp elevation of 103; @ 6PM c/o h/a & weakness in legs; Temp elevation to 105 x 3 during noc; APAP & cool cloths administered every four hrs; 9AUG91 still c/o h/a;
joint pains; muscle aches; malaise; chills; fatigue; very mild headache; This is a spontaneous report from a contactable physician reporting on himself. A 68-year-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE) (lot number EL0140/expiration date: not provided), via an unspecified route of administration, on 30Dec2020 at 05:00 PM (at the age of 68 years old) as a single dose in the left arm for COVID-19 vaccination. Relevant medical history included hypertension, gout, dyslipidemia, and dysthymia. The patient did not have any known allergies to any medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medication within two weeks were taken but were not provided. The patient did not receive any other vaccines on the same date or within 4 weeks prior to the COVID vaccine. On 31Dec2020, at 08:30 PM, the patient experienced joint pains, muscle aches, malaise, chills, fatigue, and very mild headache. The patient did not receive and treatment for these events. The outcome of the events joint pains, muscle aches, malaise, chills, fatigue, and very mild headache was recovering. Since the vaccination, the patient had not been tested for COVID-19.
Day of: Fever 102.4 , headache Next day: fatigue, sore arm Yesterday: period began 15 days early. Extremely heavy flow, no cramps yet or breast tenderness
Pain at injection site Narrative:  Patient received 2nd dose of COVID-19 vaccine (Moderna) on 03/26/2021. Unknown when started, but patient reports pain from the injection site and radiating up to shoulder, neck, and chest. Pain lasted for 2-3 days. Patient took acetaminophen on day 3, eventually pain and discomfort dissipated.
immed local react; 3-4 cm, red, indurated, & tender lasting 5 days;
Severe dizziness, 4 weeks after first shot on 02/02/2021 and continues after second shot on 03/03/2021.  Must use walking cane to remain upright.  Cannot drive or work.  Weakness
Fever (higher than 101 F); This case was reported by a physician via sales rep and described the occurrence of fever in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   In December 2019, the patient received the 1st dose of Shingrix. In December 2019, less than a week after receiving Shingrix, the patient experienced fever. On an unknown date, the outcome of the fever was recovered/resolved.   It was unknown if the reporter considered the fever to be related to Shingrix.  Additional details were provided as follows:  The age at vaccination was not reported. Post vaccination the patient experienced fever (higher than 101 fahrenheit) during 48 hours. The event resolved in 48 hours. The reporter consented to follow up.
This is a spontaneous report from a contactable consumer who reported for herself. A 73-year-old female patient received the first dose of PREVNAR 13, via an unspecified route of administration at single dose in the left arm on Jan2017 for immunisation. Medical history included heart condition (had for 20 years). Concomitant medication included influenza vaccine (FLU) in the right arm on Jan2017 for immunisation. In Jan2017, the patient got very sick with outcome of unknown. On an unspecified date in 2017, limited movement of her left arm with outcome of not recovered, pain in left arm with outcome of not recovered. The events were described as follows: She got very sick the next day after the shot and was in bed for a whole week. She felt like she had pneumonia. Pain in left arm started about a week after she got the shot. A few weeks after getting the shot she had the limited movement in her left arm. The patient underwent lab tests and procedures which included on unknown date X-ray: showed bone and it was negative for a fracture. Therapeutic measures were taken as a result of the events included Cortisone shot, but it did not do anything.
Child experienced what seemed to be a vasovagal syncope response after vaccination. Child became flushed and sweaty immediately after vaccination. Child's limbs became weak and child proceeded to vomit. Pt oxygen saturation at 10:22 am was 49%, heart rate 49 bpm, blood pressure <82. Child was put on 2L oxygen via nasal cannula and given water. At 10:26 am child's heart rate was 60 and oxygen saturation was 100%. 10:27 am heart rate was 84 bpm and then up to 93 bpm. At 10:29 blood pressure was <94. At 10:32 am child's blood pressure was 96/62. At 10:35 child's oxygen saturation on room air was 94%, heart rate 80 bpm, and blood pressure 98/56. At this time child felt much better, was responsive, back to baseline. Child left room with school nurse in wheelchair to lay down in nurse's office.  This nurse phoned parents at 12:45 pm 5/6/22 and parents of child stated child was feeling well and resting. RN
Pt initially said he need a booster, booster was given, upon taking card I noticed it was a second dose and not a booster.
Patient feels nauseated starting approximately 5 minutes after receiving 2nd dose of Moderna COVID-19 vaccine.  At 3:15pm:  BP 133/73, HR=100  O2 sats = 99%.  Patient feels queasy, but better.  Patient clinically stable.  Patient released from clinic at 3:23pm.
Swelling mild at site of injection, day 2 afterward the site appeared a red whelp, soreness several days, a knot or hard bump at injection site - still there. Sensation of fever some days after, sweats.
Left sided chest pain; Some discomfort in the right shoulder/ Joint pain; Headache; Cervical lymphoadenopathy; Severe fatigue/experiencing so much fatigue that they cannot work; A spontaneous report was received from a 58-years-old  female patient who was a Healthcare Professional received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events  severe fatigue, left sided chest pain, ongoing cervical lymphadenopathy some discomfort in the right shoulder, joint pain, headaches.  The patient's medical history was not provided.   The patient past medication history included vitamins and chinese herbs for unknown indication.  No relevant concomitant medications were reported.  On 23 Jan 2021, prior to the onset of the events the patient received her first of two planned doses of mRNA-1273 (lot/batch: 025J20-2A) via unknown route at unknown anatomical location for prophylaxis of COVID-19 infection.  On 23 Jan 2021, the patient experienced the events had severe fatigue/so much fatigue that cannot work, when she was walking she got exhausted, left sided chest pain, ongoing cervical lymphadenopathy that comes and goes, some discomfort in the right shoulder, Joint pain and headaches all of that had gone about the fifth or sixth day. The patient was taking supplements (vitamins and chinese herbs) before taking the vaccine but stopped after because she was confused about the cause of the symptoms.  Treatment details included None.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of event(s) headaches, joint pain was considered resolved on 29 Jan 2021.  The outcome of events has severe fatigue/so much fatigue that cannot work, when she was walking she got exhausted, left sided chest pain, ongoing cervical lymphadenopathy that comes and goes, some discomfort in the right shoulder was unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
On July 11, 2021, I spiked a fever out of the blue and without warning.  Call my family [physician on July 12th for an appointment which /was made for Wednesday 7/13 in the afternoon.  By Wednesday,  7/13 I was in too much pain to wait.  I went to the emergency room for diagnosis and pain relief.
Restless legs went away after Covid Vaccine; This is spontaneous report from a contactable consumer (patient) via Pfizer sponsored program Covax US Support. A male patient of an unspecified age received first and second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for Injection, Batch/Lot number: Un-known) both via an unspecified route of administration on an unspecified date in 2021 as single dose for covid-19 immunisation. The patient medical history included ongoing restless legs syndrome (has restless legs and has had it for most of his life, 20 years). The patient concomitant medications were not reported. The patient experienced that restless legs went away after he had the first Pfizer Covid Vaccine. It was about 4 months prior. Patient got the second vaccine, and it was coming back a little bit but not as bad as it was. Patient stated that the Covid vaccine made his restless legs better. Patient asked if he can get a third vaccine. The outcome of the event was unknown.  Information on the Lot/Batch number has been requested.
received vaccine 1 month after expiration date; This case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 11-year-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA380A, expiry date 31st August 2021) for prophylaxis.   On 30th September 2021, the patient received Menveo. On 30th September 2021, unknown after receiving Menveo, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.  Additional details were provided as follows: The patient received a vaccine one month after the expiration date, which led to expired vaccine used. The reporter consented to follow up.
No adverse event; Second dose of the Moderna COVID-19 vaccines was administered after the published expiration date of 04Dec2022; First dose was administered on 10-Aug-2022 and second dose was administered on 05-Dec-2022; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Second dose of the Moderna COVID-19 vaccines was administered after the published expiration date of 04Dec2022), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose was administered on 10-Aug-2022 and second dose was administered on 05-Dec-2022) and NO ADVERSE EVENT (No adverse event) in a 10-month-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AS1414B) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: Influenza. Past adverse reactions to the above products included No adverse event with Influenza.   On 10-Aug-2022, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Dec-2022, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .25 milliliter. On 05-Dec-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Second dose of the Moderna COVID-19 vaccines was administered after the published expiration date of 04Dec2022) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose was administered on 10-Aug-2022 and second dose was administered on 05-Dec-2022). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Second dose of the Moderna COVID-19 vaccines was administered after the published expiration date of 04Dec2022), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose was administered on 10-Aug-2022 and second dose was administered on 05-Dec-2022) and NO ADVERSE EVENT (No adverse event) outcome was unknown.      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Second dose of the Moderna COVID-19 vaccines was administered after the published expiration date of 04Dec2022) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First dose was administered on 10-Aug-2022 and second dose was administered on 05-Dec-2022).    Concomitant medications details were not reported by the reporter.  Reportedly the patient received other vaccines in the 4 weeks prior to COVID-19 vaccine.  Patient had not reported any symptoms.  Treatment details were not reported by the reporter.